GR-MD-02 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypertension, Portal

Conditions

Hypertension, Portal

Trial Timeline

Jun 1, 2015 → Oct 1, 2017

NCT ID

NCT02462967

About GR-MD-02 + Placebo

GR-MD-02 + Placebo is a phase 2 stage product being developed by Galectin Therapeutics for Hypertension, Portal. The current trial status is completed. This product is registered under clinical trial identifier NCT02462967. Target conditions include Hypertension, Portal.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02421094	Phase 2	Completed	Sep 1, 2015	Sep 27, 2016	Nonalcoholic Steatohepatitis
NCT02462967	Phase 2	Completed	Jun 1, 2015	Oct 1, 2017	Hypertension, Portal
NCT01899859	Phase 1	Completed	Jul 1, 2013	Feb 1, 2015	Non-Alcoholic Steatohepatitis (NASH)

Competing Products

20 competing products in Hypertension, Portal

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
tadalafil + tadalafil	Eli Lilly	Phase 3	77
CS1 Administration	Cereno Scientific	Phase 2	47
CS1	Cereno Scientific	Pre-clinical	18
TX000045- Dose A + TX000045- Dose B + Placebo	Tectonic Therapeutic	Phase 2	44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks	Keros Therapeutics	Phase 2	44
Tirzepatide + Tirzepatide Placebo	Eli Lilly	Approved	85
L04RD1 + L04TD3	Celltrion	Phase 1	33
Azilsartan Medoxomil	Celltrion	Pre-clinical	23
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mg	Celltrion	Phase 3	77
Satralizumab (Genetical Recombination)	Chugai Pharmaceutical	Phase 2	52
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg	Yuhan	Approved	85
Telmisartan + Amlodipine + Chlorthalidone	Yuhan	Phase 1	33
Temisartan/Amlodipine+Rosuvastatin + YHP1604	Yuhan	Phase 1	33
Temisartan+Amlodipine+Rosuvastatin (Combination drug) + Temisartan+Amlodipine + Temisartan+Rosuvastatin	Yuhan	Phase 3	77
Amlodipine + Valsartan	Yuhan	Approved	85
Duowell® + Telmisartan	Yuhan	Approved	85
YHP1701 + YHR1703 + YHR1704	Yuhan	Phase 3	77
YH22189 + Twynsta 80/10mg + Crestor 20mg	Yuhan	Phase 1	33
OM 40 + OM/HCTZ 40/12.5	Daiichi Sankyo	Phase 3	77

Other Products from Galectin Therapeutics

belapectin + PlaceboPhase 2/3

GR-MD-02 + PlaceboPhase 2

GR-MD-02Phase 2

GM-CT-01 plus 5-FluorouracilPhase 2

GM-CT-01 + 5-Fluorouracil, Leukovorin, bevacizumabPhase 2